Nicholas Choong

Nicholas Choong

Company: Seagen

Job title: VP, Clinical Development


Delving into Disitamab Vedotin: A Novel HER2 ADC 12:15 pm

Disitamab vedotin is a HER2 ADC with an antibody designed to maximise drug delivery with higher affinity and internalisation rate as compared to trastuzumab in preclinical models Highlighting DV’s encouraging monotherapy clinical data across a range of HER2 expressing solid tumours, and combination activity with anti-PD1 in urothelial cancerRead more

day: Track C - Day 1 - AM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.